Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Executive Chairman | 322.69k | -- | 1956 |
| Ms. Leslie Chong | CEO, MD & Executive Director | 1.39M | -- | -- |
| Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD | CFO & Company Secretary | 521.65k | -- | 1967 |
| Dr. Bradley Glover M.B.A., Ph.D. | Chief Operating Officer | 876.97k | -- | 1969 |
| Dr. Joseph Paul Woodard Jr., M.D. | Chief Medical Officer | 1M | -- | -- |
| Ms. Ursula McCurry | Chief Clinical Operations Officer | -- | -- | -- |
| Dr. John Byon | Senior Vice President of Clinical Development | -- | -- | -- |
Imugene Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.
Corporate Governance
Upcoming Events
February 26, 2025 at 9:09 PM UTC - March 2, 2025 at 9:09 PM UTC
Imugene Limited Earnings Date
Recent Events
Recent Events Information Not Available